Compare KraneShares Electric Vehicles and Future Mobility (KARS) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares Electric Vehicles and Future Mobility vs Viatris Inc — how do they compare? KraneShares Electric Vehicles and Future Mobility trades at $29.85, while Viatris Inc trades at $17.57 (market cap $19.79B). The key difference: Viatris Inc pays a 2.83% dividend while KraneShares Electric Vehicles and Future Mobility pays none, and Viatris Inc is trading nearer its 52-week high, KraneShares Electric Vehicles and Future Mobility nearer its low. Which is the better fit depends on your goals.
| KARS | VTRS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $38.01 | $17.39 |
52-Week Low | $23.61 | $8.74 |
Market Cap | — | $19.79B |
Enterprise Value | — | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KARS trades at $29.15, down 0.98% with a bearish technical signal from moving averages and oscillators showing mixed signals. The stock faces headwinds from sector rotation away from traditional automakers toward efficient vehicles, as highlighted by recent news. Financial ratios are unavailable, limiting fundamental clarity, but the electric vehicle ETF context suggests exposure to evolving industry dynamics.
Outlook remains cautious due to technical weakness and sector pressures, though potential exists if EV adoption accelerates. Risks include competitive threats from Chinese automakers and regulatory uncertainty. Investors should await clearer financial data to assess valuation and growth prospects amid shifting market sentiment.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KraneShares Electric Vehicles and Future Mobility
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
